A new vaccine has being developed by a Mater Research team based at The Translational Research Institute in collaboration with The University of Queensland.
The vaccine is said to have the potential to activate the body’s immune system to fight a range of cancers, including leukaemia, breast cancer, lung cancer and pancreatic cancers.
It is now ready to tried on humans following the successful outcome of preclinical studies.
It is being described as major breakthrough for cancer vaccinations, due to fact that the vaccine has the potential to treat a variety of blood cancers and malignancies.
According to Lead Researcher Associate Professor Kristen Radford.
“We are hoping this vaccine could be used to treat blood cancers, such as myeloid leukaemia, non-Hodgkin’s lymphoma, multiple myeloma, and paediatric leukaemias, plus solid malignancies including breast, lung, renal, ovarian, and pancreatic cancers, and glioblastoma,” she said.
“Our new vaccine is comprised of human antibodies fused with tumour-specific protein, and we are investigating its capacity to target human cells while activating the memory of the tumour cells.”
According to the researcher, the new vaccine has more advantages than existing vaccines. 1
“First, it can be produced as an ‘off the shelf’ clinical grade formulation, which circumvents the financial and logistical issues associated with patient-specific vaccines,” she said.
“Secondly, this prototype vaccine targets the key tumour cells required for the initiation of tumour-specific immune responses, thereby maximising potential effectiveness of treatment, while minimising potential side effects.